Hypertensive treatment and the metabolic syndrome

Research output: Contribution to journalArticle

Abstract

The prevalence of obesity, hypertension and type 2 diabetes mellitus-all part of the metabolic syndrome--is increasing in the US and worldwide. In this setting, it is important to understand the effects of antihypertensives on several components of the metabolic syndrome. Overall, has treatment of hypertension in diabetes been beneficial? To answer this question, the authors have reviewed pertinent clinical studies. The Action to Control Cardiovascular Risks in Diabetes Study (ACCORD) was a well-designed trial of 10,251 patients with type 2 diabetes mellitus that studied the effects of tight control of blood sugar, hypertension and lipids. Disappointingly, as compared with standard treatment, the use of intensive therapy to target normal glycated hemoglobin levels, tight lipid control by adding fenofibrate to a statin and aggressive blood pressure treatment with a goal of 120 mm Hg did not significantly reduce major cardiovascular events. Focusing on patients with hypertension, the authors compare these results to other studies of the same issues and speculate about reasons for the lack of benefit in ACCORD. Finally, the authors speculate on whether future treatment might be guided by genetic markers.

Original languageEnglish (US)
Pages (from-to)172-183
Number of pages12
JournalCurrent Hypertension Reviews
Volume7
Issue number3
StatePublished - Nov 2011

Fingerprint

Hypertension
Type 2 Diabetes Mellitus
Fenofibrate
Lipids
Therapeutics
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Glycosylated Hemoglobin A
Genetic Markers
Antihypertensive Agents
Blood Glucose
Obesity
Blood Pressure
Clinical Studies

Keywords

  • Antihypertensives
  • Diabetes mellitus
  • Hypertension
  • Metabolic syndrome
  • Obesity

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Hypertensive treatment and the metabolic syndrome. / Siegel, David; Swislocki, Arthur L.

In: Current Hypertension Reviews, Vol. 7, No. 3, 11.2011, p. 172-183.

Research output: Contribution to journalArticle

@article{09dc8f712ff24dd7b2be8063347f2726,
title = "Hypertensive treatment and the metabolic syndrome",
abstract = "The prevalence of obesity, hypertension and type 2 diabetes mellitus-all part of the metabolic syndrome--is increasing in the US and worldwide. In this setting, it is important to understand the effects of antihypertensives on several components of the metabolic syndrome. Overall, has treatment of hypertension in diabetes been beneficial? To answer this question, the authors have reviewed pertinent clinical studies. The Action to Control Cardiovascular Risks in Diabetes Study (ACCORD) was a well-designed trial of 10,251 patients with type 2 diabetes mellitus that studied the effects of tight control of blood sugar, hypertension and lipids. Disappointingly, as compared with standard treatment, the use of intensive therapy to target normal glycated hemoglobin levels, tight lipid control by adding fenofibrate to a statin and aggressive blood pressure treatment with a goal of 120 mm Hg did not significantly reduce major cardiovascular events. Focusing on patients with hypertension, the authors compare these results to other studies of the same issues and speculate about reasons for the lack of benefit in ACCORD. Finally, the authors speculate on whether future treatment might be guided by genetic markers.",
keywords = "Antihypertensives, Diabetes mellitus, Hypertension, Metabolic syndrome, Obesity",
author = "David Siegel and Swislocki, {Arthur L}",
year = "2011",
month = "11",
language = "English (US)",
volume = "7",
pages = "172--183",
journal = "Current Hypertension Reviews",
issn = "1573-4021",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Hypertensive treatment and the metabolic syndrome

AU - Siegel, David

AU - Swislocki, Arthur L

PY - 2011/11

Y1 - 2011/11

N2 - The prevalence of obesity, hypertension and type 2 diabetes mellitus-all part of the metabolic syndrome--is increasing in the US and worldwide. In this setting, it is important to understand the effects of antihypertensives on several components of the metabolic syndrome. Overall, has treatment of hypertension in diabetes been beneficial? To answer this question, the authors have reviewed pertinent clinical studies. The Action to Control Cardiovascular Risks in Diabetes Study (ACCORD) was a well-designed trial of 10,251 patients with type 2 diabetes mellitus that studied the effects of tight control of blood sugar, hypertension and lipids. Disappointingly, as compared with standard treatment, the use of intensive therapy to target normal glycated hemoglobin levels, tight lipid control by adding fenofibrate to a statin and aggressive blood pressure treatment with a goal of 120 mm Hg did not significantly reduce major cardiovascular events. Focusing on patients with hypertension, the authors compare these results to other studies of the same issues and speculate about reasons for the lack of benefit in ACCORD. Finally, the authors speculate on whether future treatment might be guided by genetic markers.

AB - The prevalence of obesity, hypertension and type 2 diabetes mellitus-all part of the metabolic syndrome--is increasing in the US and worldwide. In this setting, it is important to understand the effects of antihypertensives on several components of the metabolic syndrome. Overall, has treatment of hypertension in diabetes been beneficial? To answer this question, the authors have reviewed pertinent clinical studies. The Action to Control Cardiovascular Risks in Diabetes Study (ACCORD) was a well-designed trial of 10,251 patients with type 2 diabetes mellitus that studied the effects of tight control of blood sugar, hypertension and lipids. Disappointingly, as compared with standard treatment, the use of intensive therapy to target normal glycated hemoglobin levels, tight lipid control by adding fenofibrate to a statin and aggressive blood pressure treatment with a goal of 120 mm Hg did not significantly reduce major cardiovascular events. Focusing on patients with hypertension, the authors compare these results to other studies of the same issues and speculate about reasons for the lack of benefit in ACCORD. Finally, the authors speculate on whether future treatment might be guided by genetic markers.

KW - Antihypertensives

KW - Diabetes mellitus

KW - Hypertension

KW - Metabolic syndrome

KW - Obesity

UR - http://www.scopus.com/inward/record.url?scp=84857411527&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857411527&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84857411527

VL - 7

SP - 172

EP - 183

JO - Current Hypertension Reviews

JF - Current Hypertension Reviews

SN - 1573-4021

IS - 3

ER -